Last reviewed · How we verify
Daratumumab-hyaluronidase
Daratumumab-hyaluronidase is a monoclonal antibody-drug conjugate that targets CD38 on cancer cells.
Daratumumab-hyaluronidase is a monoclonal antibody-drug conjugate that targets CD38 on cancer cells. Used for Multiple myeloma.
At a glance
| Generic name | Daratumumab-hyaluronidase |
|---|---|
| Also known as | Darzalex FASPRO® |
| Sponsor | Eastern Cooperative Oncology Group |
| Drug class | Monoclonal antibody-drug conjugate |
| Target | CD38 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Daratumumab is a monoclonal antibody that binds to CD38, a protein found on the surface of multiple myeloma cells. Hyaluronidase is an enzyme that helps to break down hyaluronic acid, a component of the extracellular matrix, allowing the monoclonal antibody to penetrate deeper into the tumor tissue.
Approved indications
- Multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Muscle spasms
- Headache
Key clinical trials
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
- Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing (PHASE2)
- Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease (PHASE2)
- A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma (PHASE3)
- Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure (EARLY_PHASE1)
- Daratumumab in STK11 Mutated NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daratumumab-hyaluronidase CI brief — competitive landscape report
- Daratumumab-hyaluronidase updates RSS · CI watch RSS
- Eastern Cooperative Oncology Group portfolio CI